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While allosteric activation of AMPK is triggered only
by AMP, binding of both ADP and AMP has been
reported to promote phosphorylation and inhibit
dephosphorylation at Thr172. Because cellular con-
centrations of ADP and ATP are higher than AMP, it
has been proposed that ADP is the physiological
signal that promotes phosphorylation and that allo-
steric activation is not significant in vivo. However,
we report that: AMP is 10-fold more potent than
ADP in inhibiting Thr172 dephosphorylation; only
AMP enhances LKB1-induced Thr172 phosphoryla-
tion; and AMP can cause >10-fold allosteric activa-
tion even at concentrations 1–2 orders of magnitude
lower than ATP. We also provide evidence that allo-
steric activation by AMP can cause increased phos-
phorylation of acetyl-CoA carboxylase in intact cells
under conditions in which there is no change in
Thr172 phosphorylation. Thus, AMP is a true physio-
logical regulator of AMPK, and allosteric regulation
is an important component of the overall activation
mechanism.
INTRODUCTION
AMP-activated protein kinase (AMPK) is a sensor of cellular
energy status expressed ubiquitously in almost all eukaryotic
cells. Once activated by metabolic stresses that inhibit ATP
production or accelerate ATP consumption, it triggers metabolic
changes that act to restore energy homeostasis, switching
on catabolic pathways that generate ATP while inhibiting
anabolic pathways and other ATP-requiring processes (Hardie
et al., 2011; 2012). AMPK exists as heterotrimeric complexes
comprising catalytic a subunits and regulatory b and g subunits,
each of which occurs inmammals as alternate isoforms encoded
by distinct genes. Phosphorylation of Thr172 within the activa-
tion loop of the a subunit kinase domain can cause activation
of >100-fold in cell-free assays. The major Thr172 kinase is a
complex containing the tumor suppressor kinase LKB1 (liver
kinase B1) (Hawley et al., 2003; Shaw et al., 2004; Woods556 Cell Metabolism 18, 556–566, October 1, 2013 ª2013 The Authoet al., 2003), although many cells display an alternate pathway
involving the calmodulin-dependent protein kinase, CaMKKb
(Hawley et al., 2005; Hurley et al., 2005; Woods et al., 2005).
CaMKKb is activated by increases in intracellular Ca2+, while
the LKB1 complex appears to be constitutively active (Lizcano
et al., 2004; Sakamoto et al., 2004). However, binding of adenine
nucleotides to the g subunit (Scott et al., 2004; Xiao et al., 2007;
2011) causes conformational changes that regulate the phos-
phorylation and dephosphorylation of Thr172, and hence
AMPK activity, allowing the phosphorylation state to alter
according to cellular energy status.
The regulatory adenine nucleotide-binding sites on the g sub-
units are formed by four tandemCBS repeats (Scott et al., 2004).
Crystallography of partial complexes from mammals and fungi
(Amodeo et al., 2007; Jin et al., 2007; Townley and Shapiro,
2007; Xiao et al., 2007; 2011) revealed that these have a pseudo-
symmetrical layout, generating four clefts in the center where
adenine nucleotides could bind; these sites are numbered
according to which CBS repeat bears an aspartate side chain
involved in nucleotide binding (Kemp et al., 2007). In a structure
of a mammalian complex crystallized with AMP, site 2 was
empty, while sites 1, 3, and 4 were occupied by AMP. When
ATP was soaked into the crystals, AMP was replaced by ATP
only at sites 1 and 3, so site 4 was designated a nonexchange-
able site where AMP was proposed to be permanently bound
(Xiao et al., 2007; 2011). Competitive binding studies using
fluorescent ATP derivatives suggested that the affinities for bind-
ing of AMP, ADP, and ATP at sites 1 and 3 are similar, although
site 1 appeared to have an affinity 30- to 40-fold higher than that
of site 3 for all three nucleotides (Xiao et al., 2011).
Even before the identity of the upstream kinases had been
determined, AMP binding had been reported to both promote
phosphorylation (Hawley et al., 1995) and inhibit dephosphoryla-
tion (Davies et al., 1995) of Thr172. It was recently reported that
binding of ADP, as well as AMP, inhibited dephosphorylation
(Xiao et al., 2011) and that ADP as well as AMP enhanced phos-
phorylation of Thr172 by both LKB1 and CaMKKb (Oakhill et al.,
2010; 2011). Based on these findings and the fact that cellular
ADP concentrations are usually at least one order of magnitude
higher than those of AMP, it was proposed that ADP, not AMP, is
the physiological signal that enhances net Thr172 phosphoryla-
tion and that allosteric activation by AMP may not be relevant in
the physiological context (Carling et al., 2012; Oakhill et al.,
2012). In this paper, we have reinvestigated these questions.rs
Figure 1. Effect of AMP, ADP, and 50-Nucleotidase on the Inactiva-
tion and Thr172 Dephosphorylation of AMPK by PP2Ca
Incubations without Mg2+ were used as controls.
(A) Effects of AMP and ADP on inactivation by phosphatase (PP2Ca) ± 5 mM
ATP. Protection against inactivation is defined as the activity difference in
assays with or without nucleotide expressed as a percentage of the difference
obtained with or without optimal nucleotide (30 mM for AMP and 300 mM for
ADP, both in the absence of ATP). Results were fitted to the equation: Y =
100 3 X / (EC50 + X), where Y is the percent of protection and X is the con-
centration of AMP or ADP. Data are mean ± SEM (n = 2), and curves were
generated with the equation above, using best-fit values for EC50 quoted in the
text. The vertical dotted lines show the ranges over which AMP and ADP
concentrations were estimated to change when G361 cells were treated with
100 mM berberine (Table S1 and Figure 5).
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AMP Is More Potent than ADP in Inhibiting
Dephosphorylation of Thr172
Native AMPK purified from rat liver has been consistently
reported to exhibit a greater allosteric activation by AMP (typi-
cally 3- to 4-fold; Carling et al., 1987; 1989) than bacterially
expressed rat or human complexes (typically 1.5- to 2-fold;
Sanders et al., 2007; Suter et al., 2006). We therefore used puri-
fied rat liver AMPK to reinvestigate the regulatory effects of
adenine nucleotides in cell-free assays. We first monitored the
ability of various concentrations of AMP and ADP to protect
against inactivation caused by incubation with recombinant
PP2Ca (Figure 1A). This confirmed previous results (Xiao et al.,
2011) showing that ADP, as well as AMP, protected against inac-
tivation and dephosphorylation, but AMP was effective at lower
concentrations than ADP. In the absence of ATP, the half-
maximal effect of AMP on inactivation (EC50) was at 2.6 ±
0.3 mM, whereas the half-maximal effect of ADP was at 23 ±
3 mM, almost 10-fold higher. We repeated the assays in the pres-
ence of 5mMATP (Figure 1A). As expected if ATP competes with
AMP and ADP, the EC50 for AMP increased by 75-fold to 196 ±
15 mM and for ADP by 60-fold to 1.4 ± 0.1 mM. However, the
higher potency of AMP compared with that of ADP was retained.
At this ATP concentration (which is within the physiological
range), the EC50 values for AMP and ADP were 25-fold and 3-
to 4-fold lower, respectively, than the ATP concentration. Parallel
analysis of Thr172 phosphorylation (Figure 1B) was consistent
with the activity assays.
Analysis of our commercial preparation of ADP showed that it
exhibited z1% contamination with AMP. Thus, contamination
with AMP was unlikely to explain an effect of ADP that was
only 10-fold less potent than that of AMP. However, to rule this
out we repeated the assays at saturating concentrations of
AMP and ADPwith and without the 50-nucleotidase CD73, which
hydrolyzes AMP to adenosine and phosphate, but not ADP or
ATP. While the effects of AMP were abolished as expected,
the effects of ADP were only partially reduced (Figure 1C). The
small reduction may be accounted for by hydrolysis of the small
amount of AMP contaminating the ADP, but the residual protec-
tion must be due to ADP.
AMP, but Not ADP, Enhances Phosphorylation by LKB1,
but Not CaMKKb
Both AMP and ADP have recently been reported to enhance
phosphorylation of Thr172 by LKB1 and CaMKKb, as long as
the b subunit was N-myristoylated (Oakhill et al., 2010; 2011).
Figure 2A shows that AMP promoted activation and Thr172
phosphorylation of rat liver AMPK by LKB1, but not CaMKKb.(B) Samples from incubations ± 5 mM ATP were analyzed by western blotting
using anti-pT172 and anti-AMPK-a antibodies.
(C) AMPK was incubated at 30C with PP2Ca ± Mg2+ as in (A), with or without
AMP (100 mM), ADP (300 mM), or the 50-ectonucleotidase CD73 as indicated.
The nucleotides were preincubatedwith CD73 for 5min at 30Cbefore starting
the reaction by the addition of AMPK. Kinase activities (expressed as per-
centages of activity in control without Mg2+, mean ± SEM, n = 3) and anti-
pT172 blots are shown. ***Significantly different from controls without AMP/
ADP (p < 0.001); yyysignificantly different from control without CD73 (p < 0.001);
ns, not significantly different from control without AMP or CD73.
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Figure 2. AMP, but Not ADP, Enhances
Thr172 Phosphorylation and Activation of
AMPK by LKB1, but Not CaMKKb
(A) Effect of AMP and ADP on activation and
Thr172 phosphorylation by LKB1 and CaMKKb.
Purified rat liver AMPK was incubated with
bacterially expressed human PP2AC to give
z95% inactivation. Okadaic acid was then added
to inhibit PP2AC, and the dephosphorylated kinase
was incubated for 10 min with MgCl2 (5 mM) and
ATP (200 mM), with or without LKB1 or CaMKKb,
andwith or without AMP or ADP (300 mM). Aliquots
were taken for kinase assays (top; mean ± SEM,
n = 3) or western blotting (bottom). Kinase activ-
ities are expressed as percentages of the initial
kinase activity prior to dephosphorylation.
(B)Concentrationdependenceof the effect ofAMP
on AMPK activation by LKB1 (other conditions are
as in A; mean ± SEM, n = 3). Data were fitted to
the equation Y = basal + ([{activation 3 basal 
basal} 3 X] / [EC50 + X]), where Y is kinase activity
and X is AMP concentration. The curve was
generated using the following best-fit parameters:
basal, 37% ± 3%; activation, 2.8 ± 0.3-fold; EC50,
160 ± 60 mM. The vertical dotted lines show the
range over which AMP concentration was esti-
mated to change when G361 cells were treated
with 100 mM berberine (Table S1 and Figure 5).
(C) Time course of AMPK activation by LKB1.
Incubations contained no additions (open circles),
300 mM AMP (filled circles), 300 mM ADP
(squares), or 300 mMADP plus the 50-nucleotidase
CD73 (triangles). Kinase activities are expressed
as percentages of the initial kinase activity prior to
dephosphorylation.
(D) Rat liver AMPK was incubated with or without LKB1 (amounts as in A), with or without MgCl2 (5 mM), and with or without PP2Ca, and samples were analyzed
by western blotting. The bar chart at the top (mean ± SEM, n = 3) shows quantification by densitometry of the blots at the bottom (ratio of signal with anti-pT172
and anti-AMPK-a, arbitrary units). ***Significantly different (p < 0.001); ns, not significantly different from control without additions by one-way ANOVA with
Dunnett’s multiple comparison test.
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centration of ADP (300 mM) with either upstream kinase. Fig-
ure 2B shows the dependence of activation by LKB1 on AMP
concentration; it caused 2.8 ± 0.2-fold stimulation with EC50 at
160 ± 60 mM AMP. This relatively high EC50 would explain why
contamination of 300 mM ADP with 1% AMP would not be suffi-
cient to generate an apparent effect of ADP. Figure 2C show time
courses for the effects of AMP and ADP on activation of AMPK
by LKB1. At the 10 min time point (as used in Figure 2A), we
did not observe any effect of ADP, although a small stimulatory
effect became evident at later time points. This appeared to be
due to generation of AMP from ADP during the assay, because
it was abolished by the inclusion of 50-nucleotidase (Figure 2C).
Our original demonstration that AMP promoted Thr172 phos-
phorylation on rat liver AMPK (Hawley et al., 1995) by upstream
kinase (later shown to be an LKB1-STRADa-MO25a complex;
Hawley et al., 2003) was questioned on the basis that the effects
might be explained by contamination with a Mg2+-dependent,
protein phosphatase M (PPM) family phosphatase. Inhibition
by AMP of Thr172 dephosphorylation by a PPM phosphatase,
which would be insensitive to the added okadaic acid, would
lead to an apparent increase in net phosphorylation (Sanders
et al., 2007). Our AMPK preparation is purified z1,000-fold
through six purification steps, whereas that used by Sanders558 Cell Metabolism 18, 556–566, October 1, 2013 ª2013 The Authoet al. (2007) was only purified through the first two. Nevertheless,
to rule this out we carried out mock phosphorylation incubations
lacking ATP, which showed that incubation of AMPK with LKB1
and Mg2+ caused no Thr172 dephosphorylation, unless exoge-
nous PP2Ca was added (Figure 2D).
AMP Causes a Large Allosteric Activation of AMPK,
Even at High ATP Concentrations
Using a high-pressure liquid chromatography (HPLC)-based
assay that allowed simultaneous measurement of peptide sub-
strate and product and adenine nucleotides, it was reported
that commercial preparations of ATP were contaminated with
low levels of AMP, which could also be generated during assays,
most likely by nonenzymic breakdown of ADP (Suter et al., 2006).
To minimize these problems, we utilized freshly prepared ATP
and very short assay times (5 min). To address the question of
whether AMP is capable of competing with ATP at the allosteric
sites, we also conducted assays not only at 200 mMATP as in the
standard assay, but also at the more physiological ATP concen-
trations of 1 and 5 mM. We obtained a family of bell-shaped
curves in which AMP activated AMPK at low concentrations
and then inhibited at higher concentrations (Figure 3A). The
inhibitory effects were due to competition of AMP with ATP at
the catalytic site, because if we assayed bacterially expressedrs
Figure 3. Allosteric Activation by AMP, and Inhibition at High AMP
Concentrations, of Rat Liver AMPK and GST Fusions of the Isolated
a1 and a2 Kinase Domains
(A) Effect of increasing AMP concentrations on the activity of purified rat liver
AMPK. Data points were generated at three different concentrations of ATP
(circles, 0.2 mM; squares, 1 mM; triangles, 5 mM) and were fitted to the
equation Y = basal + ([{activation 3 basal  basal} 3 X] / [EC50 + X]) 
([{activation 3 basal} 3 X] / [IC50 + X]), where Y is activity and X is the AMP
concentration. The continuous curves shown were derived using this equation
and the best-fit parameters quoted in the main text.
(B and C) Effect of increasing AMP concentrations on the activity of GST
fusions with the kinase domains of human a1 (B) and a2 (C). Data (mean ±
SEM, n = 3) were obtained at three different concentrations of ATP as in (A) and
were fitted to the equation Y = basal  (basal 3 X / [IC50 + X]). The continuous
curves shown were derived using this equation and the best-fit parameters
obtained (±SEM at 0.2, 1, and 5mMATP, respectively): a1 basal activity, 136 ±
5, 404 ± 6, and 598 ± 22 nmol/min/mg; IC50 for a1, 2.4 ± 0.4, 3.3 ± 0.3, and 23 ±
68 mM; a2 basal activity, 260 ± 6, 351 ± 7, and 669 ± 8 nmol/min/mg; IC50 for
a2, 3.2 ± 0.4, 13 ± 1.4, and 18 ± 1.4 mM. The vertical dotted lines show the
range over which AMP concentration was estimated to change when G361
cells were treated with 100 mM berberine (Table S1 and Figure 5).
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Cellglutathione S-transferase (GST) fusions of the isolated a1 or a2
kinase domains (after phosphorylation by LKB1), we no longer
observed activation by AMP but still observed the inhibitory
effects (Figures 3B and 3C); these only occurred at AMP concen-
trations above 1 mM, which are unlikely to be physiologically
relevant.
The bell-shaped curves in Figure 3A shifted to higher AMP
concentrations as ATP increased, consistent with the idea that
ATP competes with AMP both at the activating site(s) on the g
subunit and at the catalytic site on the a subunit. When we fitted
the data to a simple model (see Figure 3 legend) that assumed
single activating and inhibitory sites for AMP, we obtained
good fits (continuous curves in Figure 3A) with the following
parameters (±SEM at 0.2, 1, and 5 mM ATP, respectively): basal
activity = 372 ± 16, 266 ± 14, and 226 ± 23 mmol/min/mg; EC50 for
activation by AMP = 5.3 ± 0.4, 22 ± 1.1, and 137 ± 14 mM; IC50 for
inhibition by AMP = 1.9 ± 0.092, 7.1 ± 0.33, and 22 ± 3 mM;
degree of activation by AMP = 5.4 ± 0.2, 10 ± 0.5, and 13 ±
1.3-fold. Thus, even when the ATP concentration was 5 mM
(similar to the concentration estimated in unstressed cells;
Imamura et al., 2009), AMP caused a large allosteric activation
(13-fold) with a half-maximal effect at 140 mM.
Increased Phosphorylation of Acetyl-CoA Carboxylase
in LKB1 Null Cells Treated with AMPK Activators
To study the relative importance of allosteric activation versus
Thr172 phosphorylation in intact cells, we initially utilized G361
cells, a humanmelanoma line that lacks LKB1. In LKB1 null cells,
agents that increase cellular AMP do not increase Thr172 phos-
phorylation (Hawley et al., 2003), so they should work entirely via
allosteric mechanisms, while agents that increase intracellular
Ca2+ and activate CaMKKb work entirely via increased Thr172
phosphorylation. As expected, in G361 cells the natural product
berberine (an inhibitor of respiratory chain complex I; Hawley
et al., 2010) did not cause increased phosphorylation of Thr172
and failed to increase AMPK activity measured in washed immu-
noprecipitates (in which any effects of allosteric activation in the
intact cell would have been lost). By contrast, the Ca2+ ionophore
A23187 markedly increased Thr172 phosphorylation and kinase
activity (Figure 4A). Despite this, berberine increased phosphor-
ylation of the downstream target acetyl-CoA carboxylase (ACC)
to a larger extent than A23187 did. As expected, the CaMKK
inhibitor STO609 blocked the effect of A23187 on AMPK activa-
tion and Thr172 phosphorylation. It also reduced the low Thr172
phosphorylation and AMPK activities observed under basal con-
ditions and after berberine and reduced the effect of 100 mM
berberine on ACC phosphorylation, suggesting that the low,
basal CaMKKb activity was sufficient to generate some Thr172
phosphorylation even without A23187 treatment.
We carried out similar experiments using another AMPK acti-
vator, A769662, which does not increase cellular AMP or ADP
but acts instead by direct binding to AMPK at site(s) distinct
from those used by adenine nucleotides, causing both allosteric
activation and inhibition of Thr172 dephosphorylation (Go¨rans-
son et al., 2007; Hawley et al., 2010; 2012). The effects
of A23187 and two different concentrations of A769662 on
ACC phosphorylation were very similar and were reduced by
STO609 (Figure 4B). However, the results with A769662 bore
similarities to those with berberine in that A769662 had no effectMetabolism 18, 556–566, October 1, 2013 ª2013 The Authors 559
Figure 4. Effects of AMPK Activators and the CaMKK Inhibitor
STO609 on Phosphorylation and Activation of AMPK and Phosphor-
ylation of ACC in G361 Cells
(A) Effects of A23187 (10 mM) or berberine (100 and 150 mM) in the presence
and absence of STO609 (2.5 mM).
(B) Effects of A23187 (10 mM) or A769662 (50 and 100 mM) in the presence and
absence of STO609 (2.5 mM). Cells were incubated with the indicated agents
for 1 hr, and lysates were analyzed using immunoprecipitate kinase assays
(mean ± SD, n = 3) and western blotting. Significantly different from control
without STO609: *p < 0.05, **p < 0.01, ***p < 0.001; significantly different from
control without AMPK activator: yyy p < 0.001.
Figure 5. Effects of Treatment of G361 Cells with AMPK Activators
on Phosphorylation of ACC, Phosphorylation and Activity of AMPK,
Cellular ADP:ATP Ratios, and Calculated Cellular AMP
(A–C) Effects of treatment of G361 cells with AMPK activators on phosphor-
ylation of ACC, phosphorylation and activity of AMPK (A), cellular ADP:ATP
ratios (B), and calculated cellular [AMP] (C). Replicate dishes of cells (n = 3)
were incubated for 1 hr with A23187 (10 mM), berberine (100 mM), A769662
(100 mM), or an equivalent concentration of vehicle (DMSO) and then lysed in
parallel in neutral detergent buffer for measurement of AMPK activity in
immunoprecipitates (top) or western blotting (bottom), or in perchloric acid for
analysis of ADP:ATP ratios (center). AMP concentrations (see Table S1) were
calculated as described in Experimental Procedures. Data are mean ± SD.
Significantly different from DMSO control: ***p < 0.001.
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that it strongly enhanced ACC phosphorylation. Thus, like
berberine, in these cells A769662 appears to be promoting
ACC phosphorylation entirely by allosteric activation of AMPK.
Figure 5 shows the results of experiments in G361 cells in
which the effects of A23187, berberine, and A769662 on
AMPK activity, Thr172 phosphorylation, and cellular ADP:ATP560 Cell Metabolism 18, 556–566, October 1, 2013 ª2013 The Authoratios were compared. All three agents caused increased ACC
phosphorylation, but only A23187 caused increased Thr172
phosphorylation or AMPK activity. As expected, berberine
increased the cellular ADP:ATP ratio, unlike A23187 orrs
Figure 6. Evidence that ACC Phosphorylation in G361 Cells Is Medi-
ated by AMPK, and Effects of A23187 and Berberine in AMPK
Knockout MEFs Expressing a1-T172D Mutant
(A) FLAG-tagged inactive (D157A) mutant of AMPK-a2 was stably expressed
by homologous recombination in G361 cells carrying an Flp recombinase
target site (see Experimental Procedures) to generate dominant-negative
(DN) cells. The graph shows AMPK activity (mean ± SEM, n = 4) measured in
immunoprecipitates from control (WT) and DN cells with and without
treatment with 10 mM A23187, while the pictures below show results of
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CellA769662 (Figure 5B). The cellular AMP content was too low to
directly measure using our methodology, but we estimated its
cellular concentration from the ADP:ATP ratios (Table S1, avail-
able online, and Figure 5C) by assuming that the adenylate
kinase reaction was at equilibrium. Estimated AMP concentra-
tions did not change in response to A23187 or A769662 but
increased 6- to 7-fold in response to berberine (from 42 ± 3 to
270 ± 50 mM). This corresponds well with the range of concentra-
tions over which we found that AMP causes inhibition of dephos-
phorylation (see Figure 1A, where the estimated change in ADP is
also shown) and allosteric activation (see Figure 3A) when these
effects were measured in cell-free assays in the presence of
5 mM ATP. It also corresponds with the concentrations at which
AMP promoted phosphorylation (see Figure 2B), although that
was only measured at 200 mM ATP.
ACC Phosphorylation Is Mediated by AMPK
To confirm that ACC phosphorylation in G361 cells was cata-
lyzed by AMPK, we generated cells stably expressing a FLAG-
tagged, kinase-inactive mutant (D157A) of AMPK-a2. This
mutant was expected to act in a dominant-negative manner by
competing with the endogenous a subunits (primarily a1) for
binding to b and g. Figure 6A confirms that these cells did
express recombinant a2 as shown by probing blots with anti-
a2 or anti-FLAG antibodies; the expression of a1 was reduced,
but not eliminated. In addition, basal and A23187-stimulated
AMPK activity was decreased byz70% (Figure 6A), confirming
that the mutant was exerting a dominant-negative effect. The
phosphorylation of ACC in response to both A23187 and
A769662was reduced to an extent similar to that of the reduction
in AMPK activation (Figure 6), confirming that both effects were
mediated largely, if not entirely, by AMPK.
Berberine Increases ACCPhosphorylation, Even inCells
Expressing a T172D Mutant
As another approach to assess the role of allosteric activation,
we used AMPK-a1/ and AMPK-a2/ mouse embryo fibro-
blasts (AMPK KO MEFs) (Laderoute et al., 2006) and coex-
pressed either wild-type myc-tagged AMPK-a1 or a T172D
mutant with AMPK-b2 and AMPK-g1. The T172D mutant cannot
be phosphorylated and activated by upstream kinases but has
significant activity and retains allosteric activation by AMP (Stein
et al., 2000). We could not detect the expressed proteins using
anti-myc, anti-a1, or anti-pT172 antibodies, probably due to
low transfection efficiency. Despite this, we could detect a low,
but significant, basal AMPK activity in the cells expressing the
T172D mutant and a higher basal activity in the cells expressing
the wild-type (Figure 6C). As expected, the wild-type activity
increased following treatment with A23187 or berberine, butwestern blotting to determine expression and phosphorylation of various
proteins.
(B) As in (A), except the cells were treated with increasing concentrations of
A769662 (30, 100, 300, 500, 1000 mM) or 10 mM A23187.
(C) Effects of A23187 and berberine on AMPK activity and ACC phosphory-
lation in AMPK KO MEFs that were either untransfected or had been trans-
fected with DNAs encoding myc-tagged AMPK-a1 (wild-type or T172D
mutant), AMPK-b2, and AMPK-g1. Data are mean ± SEM (n = 4). Significant
differences from control without A23187 or berberine are shown.
Metabolism 18, 556–566, October 1, 2013 ª2013 The Authors 561
Figure 7. Estimation of Extent of Thr172 Phosphorylation in Intact
Cells, and Model for Regulation of AMPK by Adenine Nucleotides
(A) G361 cells were treated in triplicate dishes for 60 min with A23187 (10 mM)
or DMSO. Bacterially expressed AMPK (a1b2g1 complex, inactive D157A
mutant) was treated with increasing amounts of LKB1 (0.4–120 ng) and
MgATP. Equivalent amounts of AMPK from G361 cell lysates and the bacte-
rially expressed AMPK were then analyzed by SDS-PAGE and probed by
western blotting with anti-pT172 and anti-a antibodies.
(B) As in (A), except that HEK293 cells were treated with A23187 (10 mM),
berberine (100 mM), or DMSO; in this experiment, the bacterially expressed
heterotrimer was also incubated with increasing amounts of CaMKKb
(75–3,600 ng) and ATP, rather than LKB1.
(C) G361 cells (left panel) or HEK293 cells (right panel) were treated for 60 min
with or without A23187 (10 mM) or berberine (100 mM), and AMPK was
immunoprecipitated with anti-a antibodies. AMPK activity (mean ± SD, n = 3)
was then measured before and after subsequent phosphorylation using
CaMKKb and MgATP. Statistically significant from DMSO control (before
CaMKK treatment) by one-way ANOVA with Dunnett’s multiple comparison
test: *p < 0.05, ***p < 0.001.
(D) Model for the regulation of AMPK by adenine nucleotides, based on results
in this paper.
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of ACC increased significantly in response to berberine in the
cells expressing the mutant, which must have been due to allo-
steric activation. Also consistent with this, the effect of berberine
on ACCphosphorylation in the cells expressing wild-type a1was
greater than that of A23187, despite the fact that the effect on
AMPK activation was smaller.562 Cell Metabolism 18, 556–566, October 1, 2013 ª2013 The AuthoIncreases in Thr172 Phosphorylation in Intact Cells Are
Modest in Extent
Although bacterially expressed AMPK complexes can be acti-
vated >100-fold in cell-free assays by stoichiometric phosphor-
ylation of Thr172 (Suter et al., 2006), it remained unclear whether
the degree of Thr172 phosphorylation is ever close to this
maximal extent in intact cells. To address this question, we
further analyzed the effects of the Ca2+ ionophore A23187 in
G361 cells and A23187 and berberine in human embryonic
kidney 293 (HEK293) cells and estimated, using two different
methods, the proportion of the a subunits that became
phosphorylated.
First, we quantified the signal obtained by western blotting
using anti-pT172 antibody in lysates of cells treated with and
without A23187 and/or berberine. The signal was calibrated
using equivalent amounts of bacterially expressed human
a1b2g1 complex (inactive a1-D157A mutant) phosphorylated
by increasing amounts of LKB1 until phosphorylation reached
a maximum. By making the assumption that this corresponded
to stoichiometric phosphorylation, and quantifying the blots by
densitometry, we were able to estimate the stoichiometry of
phosphorylation in the intact cells. Figure 7A shows results
from one experiment with three replicate dishes of control and
A23187-treated G361 cells. This experiment was repeated five
times, and the average extent of phosphorylation estimated in
control cells was 4% ± 1%, increasing by an average of
3.6-fold to 13% ± 2% after A23187 treatment (mean ± SEM,
n = 5, p = 0.0033 by paired t test). We used the same method
to estimate the changes in Thr172 phosphorylation when
HEK293 cells were treated with A23187 or berberine (Figure 7B).
The estimated basal phosphorylation (27% ± 1%) was much
higher in HEK293 than in G361 cells, consistent with the pres-
ence of LKB1. This increased to 36% ± 2% in response to
A23187 and 50% ± 3% in response to berberine. A23187 and
berberine thus caused 1.3-fold and 1.9-fold increases in
Thr172 phosphorylation, respectively.
As a second approach, we immunoprecipitated AMPK from
the cells and incubated the precipitates with recombinant
CaMKKb and MgATP to fully activate them. The treatment with
A23187 in the G361 cells caused a 5.3-fold increase in AMPK
activity, but subsequent incubation of the immunoprecipitates
with CaMKKb caused further large activations to reach similar
final values (Figure 7C, left panel). This yielded estimates that
A23187 caused a 5-fold increase in Thr172 phosphorylation,
from 3.5% ± 0.7 to 18% ± 2%. A23187 and berberine both
caused increases in AMPK activity in HEK293 cells, but subse-
quent incubation of the immunoprecipitates with CaMKKb
caused further large activations up to similar final values (Fig-
ure 7C, right panel). This yielded estimates that A23187 and
berberine caused 1.6-fold and 2.6-fold increases in Thr172
phosphorylation, from 23% ± 3% to 37% ± 2% and 60% ±
4% respectively.
Thus, these two approaches were in reasonable agreement. In
the LKB1 null G361 cells, Thr172 phosphorylation was initially
very low (4%), increasing after A23187 treatment to 13%–18%.
In HEK293 cells, which express LKB1, the basal phosphorylation
was initially much higher, i.e., 23%–27%. This increased to
36%–37% in response to A23187 and 50%–60% in response
to berberine. The increases in phosphorylation in G361 cellsrs
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HEK293 cells due to A23187 and berberine were 1.5- and 2-
fold, respectively. Thus, although 50%–60% of the a subunit
became phosphorylated in berberine-treated HEK293 cells, the
actual increases in Thr172 phosphorylation were quite modest.
DISCUSSION
Three major conclusions, summarized in the model shown in
Figure 7D, can be drawn from this study:
(1) Dephosphorylation of Thr172 by PP2Ca is inhibited by
ADP and AMP, with the effects of both being antagonized
by ATP. However, AMP is about 10-fold more potent
than ADP.
(2) AMP promotes Thr172 phosphorylation in cell-free as-
says by LKB1, but not CaMKKb; ADP had no effect with
either upstream kinase. This effect of AMP was not due
to contamination with a PPM family protein phosphatase
(Sanders et al., 2007) because: (i) there was no Thr172
dephosphorylation in incubations with LKB1 and Mg2+
when ATP was omitted; (ii) the effect on LKB1-mediated
phosphorylation and activation was specific to AMP; if it
had been due to inhibition of dephosphorylation, both
AMP and ADP should have been effective.
(3) In cell-free assays, a large (13-fold) allosteric activation of
AMPK by AMP occurred even when the concentration of
ATP was 5 mM, within the normal physiological range
(Imamura et al., 2009). We also studied phosphorylation
of the downstream target acetyl-CoA carboxylase in
LKB1 null G361 cells, and in AMPK knockout embryo
fibroblasts expressing a T172D mutant, treated either
with berberine (which increases AMP) or A23187 (which
increases Ca2+ and activates CaMKKb). These experi-
ments revealed that the allosteric effect of AMP in intact
cells could be at least as important, if not more important,
than the effect of increased Thr172 phosphorylation.
Our results confirm previous results showing that the effect of
AMP on Thr172 dephosphorylation is mimicked by ADP (Xiao
et al., 2011). By carrying out assays in the presence of 50-nucle-
otidase, we also showed that the effect of ADP could only be
partially explained by its breakdown to AMP during assays.
However, we disagree with Xiao et al. (2011) in one respect.
Xiao et al. (2011) stated that ‘‘ADP provides protection of
AMPK from dephosphorylation across a similar range of concen-
trations as AMP,’’ whereas Figure 1 clearly shows that AMP is
about 10-fold more potent than ADP, irrespective of the pres-
ence or absence of 5 mM ATP. Xiao et al. (2011) also stated
that ‘‘the dose-response curve for AMP/ADP-mediated protec-
tion against (de)phosphorylation correlates with the binding
curves for these nucleotides at the weaker, rather than the
stronger, of the two binding sites.’’ However, reanalysis of their
Figure 1B suggests that the half-maximal effect of AMP on
dephosphorylation that they observed was at z7 mM. This is
close to our estimate of 3 mM and much closer to their estimate
of the KD for AMP binding at the ‘‘tight’’ (2.5 mM), rather than the
‘‘weak’’ (80 mM), site. Our very similar estimates of EC50 for the
effects of AMP on dephosphorylation (3 mM) and allosteric acti-
vation (5 mM, measured with 200 mM ATP) also throw doubt onCellthe proposal by Xiao et al. (2011) that allosteric activation is
due to binding at the tight site, whereas the effect on dephos-
phorylation is due to binding at the weak site. By contrast, our
estimate of the EC50 for the effect of AMP to promote phosphor-
ylation by LKB1 (160 mM, measured with 200 mM ATP) is closer
to their estimate of the affinity for AMP at the weak site.
Unlike Oakhill et al. (2011), we have been unable to show that
AMP promotes Thr172 phosphorylation by CaMKKb, either pre-
viously (Hawley et al., 2005) or in this study, and now also find
that ADP is unable to promote Thr172 phosphorylation by
LKB1; the reasons for these discrepancies remain unclear.
Our results reinforce the view that AMP, not ADP, is the critical
physiological activator of AMPK, and that the name AMP-acti-
vated protein kinase remains appropriate. We have confirmed
that AMP acts via three mechanisms (Figure 7C), two of which
(allosteric activation and promotion of Thr172 phosphorylation
by LKB1) are brought about only by AMP and not ADP. The third
(inhibition of Thr172 dephosphorylation) can also be caused by
ADP, but AMP is about 10-fold more potent than ADP. Since
AMP concentrations are usually about 10-fold lower than con-
centrations of ADP in intact cells (Hardie et al., 2011; Oakhill
et al., 2012), changes in both nucleotides might contribute to
the enhanced net Thr172 phosphorylation observed in cells sub-
ject to energy stress. However, inspection of Figure 1A (where
we have added dashed vertical lines to indicate the estimated
changes in AMP and ADP concentrations induced by berberine
in G361 cells), suggests that the changes in AMP would have
a larger effect on Thr172 dephosphorylation than would the
changes in ADP. AMP also increases in response to berberine
in G361 cells over a range where large effects on phosphoryla-
tion by LKB1 (Figure 2B) and on allosteric activation (Figure 3A)
were observed in cell-free assays.
Some recent reviews (Carling et al., 2012; Oakhill et al., 2012)
have cast doubt on the idea that AMP is the critical physiological
regulator of AMPK. There appear to be two main arguments
underlying this. First, allosteric activation is usually reported to
be quite modest (often <2-fold), yet stoichiometric phosphoryla-
tion of Thr172 can produce >100-fold activation. However, we
could demonstrate 13-fold allosteric activation by AMP (Fig-
ure 3A), even using an ATP concentration (5mM)within the phys-
iological range for unstressed cells (Imamura et al., 2009). In
addition, the results in Figures 7A–7C show that the 4-fold in-
crease in response to A23187 in G361 cells represents a change
from onlyz4% toz16% of maximal, stoichiometric phosphor-
ylation, whereas in HEK293 cells, where the basal phosphoryla-
tion was much higher (25%), the increases in response to
A23187 and berberine were only 1.5-fold and 2-fold. Thus,
although it is possible to obtain >100-fold activation in cell-free
assays, the changes in Thr172 phosphorylation in intact cells
occur over a much narrower range. Our experiments in G361
cells also suggest that allosteric activation of AMPK can be as
important as the effect of Thr172 phosphorylation in the overall
activation mechanism. Due to the lack of LKB1 in these cells,
berberine (which increases AMP and ADP) and A769662 (which
binds directly to AMPK) had no effect on Thr172 phosphorylation
or on AMPK activity measured in washed immunoprecipitates.
Despite this, both increased the phosphorylation of ACC, a
well-established marker for AMPK activation in intact cells, sug-
gesting that they were acting in these cells purely via allostericMetabolism 18, 556–566, October 1, 2013 ª2013 The Authors 563
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than did A23187, which acts via increased Thr172 phosphoryla-
tion). These conclusions depend on the assumption that AMPK
is the only kinase phosphorylating ACC at Ser79 in these cells,
as already demonstrated using AMPK knockouts in mouse
embryo fibroblasts, hepatocytes, and T cells (Foretz et al.,
2010; Laderoute et al., 2006; Rolf et al., 2013). To test this, we
made cells stably expressing a dominant-negative AMPK-a2
mutant and observed that the A23187-induced increase in
AMPK activity was reduced by an amount (z70%) similar to
that of the increase in ACC phosphorylation; ACC phosphoryla-
tion induced by A769662 was similarly decreased (Figures 6A
and 6B). While we cannot rule out the possibility that some of
the residual ACC phosphorylation in G361 cells expressing the
dominant-negative mutant was due to a kinase other than
AMPK, this kinase would have to be activated by both A23187
and A769662, which seems inherently unlikely.
Our results in the AMPK knockout MEFs expressing the T172D
mutant of AMPK-a1 (which retains allosteric activation by AMP;
Stein et al., 2000) also confirm that allosteric activation is an
important component of the overall activation mechanism. The
T172D mutant cannot be phosphorylated at Thr172, yet
berberine still enhanced the phosphorylation of ACC (Figure 6C).
Moreover, in the AMPK knockout MEFs expressing wild-type a1,
the effect of berberine on ACC phosphorylation was larger than
that of A23187, whereas the reverse was true for the effects on
AMPK activity. We propose that this is because the effect of
berberine on ACC phosphorylation reflects a combination of
phosphorylation and allosteric activation of AMPK induced by
AMP, whereas the effect of A23187 is only due to enhanced
phosphorylation. Our results with A769662 (Figure 4B), which
causes allosteric activation and promotion of net Thr172
phosphorylation like AMP, despite binding at a different site
(Go¨ransson et al., 2007; Hawley et al., 2012), suggest that allo-
steric activation by A769662 is also at least as important as its
effects on Thr172 phosphorylation.
It has been reported that treatment of LKB1/ MEFs with
H2O2 or AICA ribonucleotide (AICAR) led to increased ACC
phosphorylation (Shaw et al., 2004), similar to that shown in
our results using berberine in the LKB1 null G361 cell line.
Shaw et al. (2004) stated that ‘‘there was still a small, but repro-
ducible, amount of ACC phosphorylation in response to these
stimuli in LKB1-null MEFs.’’ By contrast, in LKB1 null mouse
muscle (Go¨ransson et al., 2007) or mouse hepatocytes (Foretz
et al., 2010), there was no detectable ACC phosphorylation.
The simplest explanation for these results is that the expression
of CaMKKb is higher in immortalized cells than in LKB1 null mus-
cle or hepatocytes, so AMPK is essentially inactive in the latter
and cannot be allosterically activated by AMP.
The second argument against the role of AMP as a physiolog-
ical regulator (Carling et al., 2012; Oakhill et al., 2012) is that the
affinities of the two exchangeable sites (sites 1 and 3) within the
g1 subunit were estimated to be similar for AMP, ADP, and free
ATP4 (Xiao et al., 2011). Since AMP is normally present at much
lower cellular concentrations, it has been argued that it would be
unable to compete with ADP or ATP at either regulatory site.
However, we observed 13-fold allosteric activation by AMP
even when conducting assays at 5 mM ATP. Under these condi-
tions, allosteric activation by AMP occurred from 50–500 mM,564 Cell Metabolism 18, 556–566, October 1, 2013 ª2013 The Authocorresponding nicely with our estimated increase (40–270 mM,
see Figure 3A) in AMP in G361 cells treated with berberine.
Thus, AMP can compete with ATP at the allosteric binding site(s),
even when its concentration is one to two orders of magnitude
lower than that of ATP. It is worth noting that the affinities for
AMP, ADP, and ATP of sites 1 and 3 on the g1 subunit were esti-
mated indirectly by competition with fluorescent derivatives of
ATP and ADP and by making assumptions that there were only
two exchangeable sites for each nucleotide that did not interact
(Xiao et al., 2011). However, results obtained with mutations of
aspartate residues at all three sites (1, 3, 4) suggest that these
sites do interact (Oakhill et al., 2010). Moreover, another struc-
tural analysis, in which the heterotrimer core was crystallized
independently with AMP or ATP, suggested that the so-called
nonexchangeable site 4 can bind ATP as well as AMP and that
binding of ATP at site 4 would prevent binding of other nucleo-
tides at site 3 (Chen et al., 2012). Thus, the assumptions used
to estimate the affinities for nucleotides at sites 1 and 3 (Xiao
et al., 2011) may not have been completely valid.
Another important conclusion from our results is that simply
estimating Thr172 phosphorylation as amarker for AMPK activa-
tion, which is common in the literature, can yield misleading
results in that it completely ignores the effects of allosteric activa-
tion. We would suggest that it is advisable to also monitor the
phosphorylation of at least one validated downstream target for
AMPK, such as ACC. Finally, our results with G361 cells show
that AMPK can still phosphorylate downstream targets such as
ACC in response to energetic stress, even in LKB1 null tumor
cells, although the effects may be smaller than those in LKB1-
expressing cells in that they would rely entirely on allosteric
activation, without any changes in Thr172 phosphorylation.
EXPERIMENTAL PROCEDURES
Effect of AMP and ADP on Thr172 Dephosphorylation
Rat liver AMPK (100 units/ml, 62.5 mg/ml) was incubated at 30C in Na HEPES
(50 mM; pH 7.0), NaCl (150 mM), Brij 35 (0.02% v/v), dithiothreitol (1 mM) with
MgCl2 (5 mM), and sufficient recombinant PP2Ca to yield about 70% inactiva-
tion in the absence of added nucleotide. AMP, ADP, or ATP were added at
concentrations indicated in the figure legends, and aliquots were removed
for western blotting or kinase assays. Kinase assays were performed immedi-
ately with a further dilution of 100-fold, whichwas sufficient to prevent dephos-
phorylation during the assay. Where added, the 50-ectonucleotidase CD73
was at 3.9 mg/ml (58 units/ml, where 1 unit is 1 nmol of AMP hydrolyzed per
min); it was diluted 150-fold into final kinase assays, where it did not cause a
significant effect.
Effects of AMP and ADP on Thr172 Phosphorylation
Rat liver AMPK (20 units/ml, 12.5 mg/ml) was incubated in Na HEPES (50 mM;
pH 7.0), NaCl (50 mM), Brij 35 (0.02% v/v), and dithiothreitol (1 mM) for 15 min
at 30C with sufficient PP2AC to give z95% inactivation. Okadaic acid was
added (5 mM) to inhibit PP2AC. Dephosphorylated AMPK (2 mg/ml) was then
incubated with recombinant LKB1-STRAD-MO25 complex (4 mg/ml) or
CaMKKb (1.2 mg/ml) together with MgCl2 (5 mM) and ATP (200 mM) in the
same buffer, and incubation continued for 10min, with AMP or ADP at concen-
trations given in the figures or legends. Aliquots were removed at the times
stated for kinase assays or western blotting. When added, 50-nucleotidase
was at 1.8 mg/ml; it was diluted a further 150-fold into final kinase assays
and had no effect on these. To confirm that AMPK was not contaminated
with a PPM phosphatase, we incubated AMPK that had not been treated
with PP2AC in buffer A with or without LKB1, MgCl2 (5 mM), or PP2Ca exactly
as for the rephosphorylation experiments, but omitting ATP. After 15 min at
30C, aliquots were subject to kinase assay or western blotting.rs
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Rat liver AMPK was purified as described previously (Hawley et al., 1996),
except that the final size-exclusion chromatography was not on Sephacryl
S-200, but on a Superdex 200 (HiLoad 16/60) column, equilibrated in buffer
lacking fluoride and pyrophosphate. AMPK assays in solution were performed
as previously described (Hardie et al., 2000), except that in some assays
(specified in the figure legends) the concentration of ATP was increased
from 0.2 to 1 or 5 mM, with MgCl2 concentrations also increased (5, 5.8, or
9.8 mM, respectively) to maintain a constant excess of [Mg2+] over [ATP].
Where allosteric activation by AMP was being studied, we used the SAMS
peptide as substrate. For immunoprecipitate assays, AMPK was precipitated
from lysates of G361 cells (50 mg protein) by incubation at 4C for 2 hr on a roller
mixer, with equal amounts of AMPK-a1 and -a2 antibodies noncovalently
coupled to protein G Sepharose (GE Healthcare). After washing, immunopre-
cipitates were assayed for AMPK activity using the AMARA peptide (Hardie
et al., 2000). One unit of AMPK activity phosphorylates 1 nmol of substrate
per min at 30C.
Generation of G361 Cells Expressing a Dominant-Negative a2
Mutant
G361 cells stably expressing an integrated Flp recombinase target (FRT) site
were generated using the Flp-In System (Invitrogen) following manufacturer’s
instructions. Briefly, G361 cells were transfected with the pFRTlacZeo plasmid
using FuGENE (Promega) and washed into medium containing zeocin
(100 mg/ml) after 48 hr. The medium was replaced every 3–4 days until foci
of cells could be identified and expanded. The incorporation of the FRT site
was confirmed by monitoring b-galactosidase activity. A construct encoding
human AMPK-a2 (D157A mutant) was amplified using primers designed to
encode a 50-Kpn1 site and a C-terminal FLAG tag followed by a 30-Xho1
site. The resulting PCRproduct was inserted into pcDNA5/FRT. TheG361 cells
containing an FRT site were transfected with Effectene (QIAGEN) in the
absence of zeocin, using the plasmids pOG44 (encoding Flp recombinase)
and pcDNA5/FRT/a2D157A at a ratio of 9:1. After 48 hr, hygromycin B
(100 mg/ml) was added to the medium, and the medium was changed every
3–4 days until foci of cells could be identified and expanded.
Estimation of Degree of Thr172 Phosphorylation in Intact Cells
A polycistronic plasmid expressing human a1b2g1 was generated by the Divi-
sion of Signal Transduction Therapy, University of Dundee, using previously
described methodology (Neumann et al., 2003). This was used as a template
to generate a plasmid encoding a kinase-inactive D157A mutant using the
QuikChange Site-Directed Mutagenesis Kit (Stratagene). The plasmid was
expressed in bacteria and purified using a HisTrap column (GE Healthcare)
as described previously (Hawley et al., 2012). The protein was incubated
with increasing amounts of LKB1-STRAD-MO25 complex (or CaMKKb, where
specified), ATP (200 mM), and MgCl2 (5 mM) for 15 min at 30
C in 50 mM Na
HEPES (pH 7.4), 1 mM dithiothreitol, 0.02% (v/v) Brij 35. The reaction was
stopped by the addition of SDS, with further incubation at 70C for 10 min.
Samples (corresponding to 20–40 ng of AMPK) were loaded onto the same
Bis-Tris 4%–12% polyacrylamide gels as lysates (20–40 mg protein) from cells
that had been treated with DMSO, A23187, or berberine. Membranes were
probed with the indicated antibodies, and band intensities were quantified
using LI-COR Odyssey software.
In a second approach, cell lysates were immunoprecipitated with AMPK-a1
and AMPK-a2 antibodies covalently bound to protein G Sepharose. The
Sepharose beads were incubated with CaMKKb and MgATP for 30 min at
30C and washed several times in Na HEPES buffer (pH 7.4) to remove
CaMKKb. AMPK activity was then determined using the AMARA peptide as
above.
Estimation of Cellular Adenine Nucleotide Ratios and
Concentrations
Estimation of cellular ADP:ATP ratios were performed by capillary electropho-
resis of perchloric acid extracts as described previously (Hawley et al., 2010),
except that peaks were detected by absorbance at 254 nm. AMP:ATP ratios
were estimated from ADP:ATP by assuming that the adenylate kinase reaction
was at equilibrium, so that AMP:ATP = Keq.(ADP:ATP)
2 (Hardie and Hawley,
2001), where Keq = 1.05 (Lawson and Veech, 1979).Total ATP concentrationsCell([ATP]) were estimated from the ADP:ATP ratios by assuming that [ATP] +
[ADP] + [AMP] was 5 mM, so that [ATP] = 5/(1 + ADP:ATP + AMP:ATP). Esti-
mates for [AMP] and [ADP] could then be calculated from the values for
[ATP], ADP:ATP, and AMP:ATP obtained.
Presentation of Data and Statistical Analysis
Unless stated otherwise, data presented are mean ± SEM (n = 3), with all rep-
licates in intact cell experiments from separate dishes of cells. Unless stated
otherwise, statistical analysis (GraphPad Prism 5 for Mac OSX) was by
ANOVA, using Bonferroni’s multiple comparison test of selected data sets
(*p < 0.05, **p < 0.01, ***p < 0.001; ns, not significant).
Additional Experimental Procedures
Additional experimental procedures are provided in the Supplemental
Information.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and one table and can be found with this article online at http://dx.doi.org/
10.1016/j.cmet.2013.08.019.
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